The France Diabetes Device market is expected to reach US$ 946.9 million in 2023 to US$ 1.78 billion by 2032, with a CAGR of 7.30 % from 2024 to 2032. The market for diabetes care devices in France is also being driven by factors such as the increasing incidence of diabetes and obesity, expanding awareness of diabetic care, healthcare spending, and technical improvements.
France Diabetes Device Overview
Over 3 million people in France are reported to have treated diabetes at a rate of 4.6%, and in Northern France, that number rises to 5.2%. The diabetes market is primarily driven by the need for healthcare to treat and control diabetes. Insulin pumps, continuous glucose monitoring (CGM), and self-monitoring of blood glucose (SBMG) comprise the diabetes market in France. According to a poll by the European Commission, 10% of French adults have diabetes.
But among European countries, France does not have the greatest prevalence of diabetes. At 15.4% of adult population, Germany had the highest rate of diabetes in 2022. Portugal came in second with a rate of 14.6%. However, Ireland's 4.5% diabetes rate was the lowest in all of Europe. Nevertheless, the World Health Organization (WHO) reports that almost a million French adults have a diabetes diagnosis. Furthermore, among all chronic illnesses, diabetes has the highest prevalence in France.
Of all the chronic disorders that are fully covered by France's statutory health insurance (SHI), diabetes has the highest prevalence; within the last ten years, the number of patients who are covered has doubled. One of the principal nations in the European Union is France.
The World Health Organization (WHO) estimates that one million people in France have a diabetes diagnosis. Diabetes is becoming more common in France among all age groups, which might be linked to the country's rising obesity rate as well as bad eating habits and sedentary lifestyles. In addition, it is predicted that 0.26 million people in the area have Type 1 diabetes.
Growth Drivers for the France Diabetes Device Market
France's Diabetes Population is Growing Increasing the Market for Diabetes Devices in France
Among the 59 countries that make up the IDF-EUR area is France. Furthermore, 538 million people globally and 62 million people in the Europe Region were predicted to have diabetes in 2022; by 2045, this figure is predicted to rise to 69 million. As per a report conducted by the European Commission, one in ten individuals in France have diabetes, making it the country with the greatest prevalence of chronic diabetes.
France has a high rate of diabetes, despite the fact that the regulations' goal of 80% compliance with recommended medical consultations isn't always reached. New approaches that emphasize patient and physician education and information are required to reduce the burden of complications and hospitalizations related to diabetes in order to encourage proactive therapy adjustment and diminish therapeutic inertia.
According to a 2022 article titled "Epidemiology and Health Impact of Diabetes in France," after a 5-year period, patients with diabetes type-1 reported more diabetes-related difficulties than type-2 (52.2 vs. 34.7%). Additionally, across a two-year period, patients with diabetes type-1 had a higher frequency of diabetes-related admissions (29.8% vs. 16.9%) than patients with diabetes type-2.
Growing Health Concerns
The management of diabetes is becoming more widely known, which has a big impact on patient behavior and treatment decisions. individuals are increasingly inclined to look for improved diabetes management strategies as more individuals become aware of the dangers and difficulties connected to the disease. Information regarding effective monitoring and treatment choices is being disseminated through community initiatives, educational programs, and public health campaigns. This increased awareness stimulates demand for cutting-edge diabetes solutions and gadgets as well as healthy lifestyle adoption. Healthcare providers are responding to patients' pro-active caregiving with creative solutions that improve management and overall results.
France Diabetes Device Company Analysis
The major participants in the France Diabetes Device market includes BD, Medtronic, Tandem Diabetes Care, Novo Nordisk A/S, Roche, Abbott Laboratories, Eli Lilly, Ypsomed AG, Dexcom Inc.
France Diabetes Device Company News
In September 2023, According to Dexcom, those with diabetes can now access their Dexcom ONE system in France, which provides real-time continuous glucose monitoring (CGM). This development in diabetes technology accessibility is a major win for the diabetic community, as it will make this life-saving equipment available to an extra 500,000 diabetics in France.
In April 2022, the development and commercialization of an integrated automated insulin delivery (AID) system is set to alleviate the burden of diabetes treatment for individuals living in European countries, according to a partnership between CamDiab and Ypsomed. The goal of the new integrated AID system is to link the world's smallest and most accurate continuous glucose monitoring sensor, the Abbott FreeStyle Libre 3, to CamDiab's CamAPS FX mobile app. From there, the app connects to Ypsomed's mylife YpsoPump, enabling an automated and intelligent process for insulin delivery based on real-time glucose data.
Types - Industry is divided into 4 viewpoints:
1. Self-Monitoring Devices
2. Continuous Glucose-Monitoring Devices
3. Insulin Pumps
4. Insulin Pens
Distribution Channel - Industry is divided into 4 viewpoints:
1. Hospital Pharmacies
2. Retail Pharmacies
3. Diabetes Clinics/Centers
4. Online Pharmacies
All companies have been covered with 5 viewpoints:
1. Overviews
2. Key Persons
3. Recent Developments & Strategies
4. Product Portfolio & Product Launch in Last 1 Year
5. Revenue
Company Analysis
1. BD
2. Medtronic
3. Tandem Diabetes Care
4. Novo Nordisk A/S
5. Roche
6. Abbott Laboratories
7. Eli Lilly
8. Ypsomed AG
9. Dexcom Inc.
Key Questions Answered in Report:
1. How big is the France Diabetes Device industry?
2. What is the France Diabetes Device industry growth rate?
3. Who are the key players in France Diabetes Device industry?
4. What are the factors driving the France Diabetes Device industry?
5. Which Region held the largest market share in the France Diabetes Device industry?
6. What segments are covered in the France Diabetes Device Market report?
Table of Contents
Companies Mentioned
- BD
- Medtronic
- Tandem Diabetes Care
- Novo Nordisk A/S
- Roche
- Abbott Laboratories
- Eli Lilly
- Ypsomed AG
- Dexcom Inc
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 946.9 Million |
| Forecasted Market Value ( USD | $ 1784.6 Million |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | France |
| No. of Companies Mentioned | 9 |
